absolutely as a lender they have plenty at their discretion - they would delve into one off payments and also take into account the significant tapering off of R&D expenditure with most of the trials coming to an end. I also noted they reduced their facility to mesoblast on that 4c, so possibly they mitigated some of this risk.
Ann: Trading Halt, page-146
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.08 | $4.300M | 3.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 22 | 25260 | $1.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 50560 | 19 |
View Market Depth
| Last trade - 15.00pm 10/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |